

Carla De Giovanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9282732/publications.pdf>

Version: 2024-02-01

111
papers

4,365
citations

101384

36
h-index

114278

63
g-index

112
all docs

112
docs citations

112
times ranked

4728
citing authors

#	ARTICLE	IF	CITATIONS
1	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. <i>Scientific Reports</i> , 2021, 11, 1563.	1.6	6
2	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. <i>Cells</i> , 2021, 10, 1808.	1.8	2
3	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	2.1	14
4	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	1.7	7
5	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	1.1	7
6	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <i>Cancers</i> , 2019, 11, 1889.	1.7	15
7	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2018, 7, e1465164.	2.1	3
8	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	0.8	19
9	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	2.2	11
10	Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. <i>Human Molecular Genetics</i> , 2014, 23, 1453-1466.	1.4	96
11	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	2.2	27
12	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	0.8	12
13	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	0.8	10
14	Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. <i>Cancer & Metabolism</i> , 2013, 1, 11.	2.4	75
15	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11
16	Preclinical HER-2 Vaccines: From Rodent to Human HER-2. <i>Frontiers in Oncology</i> , 2013, 3, 151.	1.3	7
17	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. <i>PLoS Pathogens</i> , 2013, 9, e1003155.	2.1	36
18	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. <i>British Journal of Cancer</i> , 2012, 107, 1302-1309.	2.9	8

#	ARTICLE	IF	CITATIONS
19	The Molecular Basis of Herpesviruses as Oncolytic Agents. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1795-1803.	0.9	4
20	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 ^{-/-} ;Il2rg ^{-/-} Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	1.1	78
21	HERPESVIRUSES AS ONCOLYTIC AGENTS. , 2012, , 223-250.		0
22	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. <i>Vaccine</i> , 2011, 29, 4690-4697.	1.7	4
23	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. <i>Current Drug Targets</i> , 2011, 12, 1957-1973.	1.0	39
24	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 319-326.	2.0	316
25	Rethinking herpes simplex virus: the way to oncolytic agents. <i>Reviews in Medical Virology</i> , 2011, 21, 213-226.	3.9	63
26	A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene <i>MTND1</i> , an <i>Oncojanus</i> Function. <i>Cancer Research</i> , 2011, 71, 6220-6229.	0.4	90
27	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	1.3	10
28	Immunoprevention and Immunotherapy of Mammary Carcinoma. <i>Breast Journal</i> , 2010, 16, S39-S41.	0.4	3
29	A Better Immune Reaction to ErbB-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. <i>Cancer Research</i> , 2010, 70, 2604-2612.	0.4	54
30	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.4	78
31	High metastatic efficiency of human sarcoma cells in Rag2 ^{-/-} double knockout mice provides a powerful test system for antimetastatic targeted therapy. <i>European Journal of Cancer</i> , 2010, 46, 659-668.	1.3	26
32	A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome. <i>Human Gene Therapy</i> , 2009, 20, 453-464.	1.4	11
33	Delivery of CD44 shRNA/Nanoparticles within Cancer Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 12432-12446.	1.6	84
34	Molecular and cellular biology of rhabdomyosarcoma. <i>Future Oncology</i> , 2009, 5, 1449-1475.	1.1	91
35	Oncolytic herpes virus retargeted to HER-2. <i>Cell Cycle</i> , 2009, 8, 2859-2860.	1.3	3
36	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	3.3	83

#	ARTICLE	IF	CITATIONS
37	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 754-761.	1.9	20
38	APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. <i>European Journal of Cancer</i> , 2009, 45, 2731-2735.	1.3	7
39	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	1.7	1
40	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.4	47
41	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007, 121, 88-94.	2.3	5
42	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	0.9	8
43	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. <i>Oncology Reports</i> , 2007, 18, 451-6.	1.2	4
44	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. <i>European Journal of Cancer</i> , 2006, 42, 680-687.	1.3	2
45	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	2.0	14
46	A Limited Autoimmunity to p185 ^{neu} Elicited by DNA and Allogeneic Cell Vaccine Hampers the Progression of Preneoplastic Lesions in HER-2/NEU Transgenic Mice. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 351-363.	1.0	8
47	New Target Antigens for Cancer Immunoprevention. <i>Current Cancer Drug Targets</i> , 2005, 5, 221-228.	0.8	16
48	Cancer immunoprevention. <i>Future Oncology</i> , 2005, 1, 57-66.	1.1	43
49	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1205-1216.	1.9	43
50	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.4	83
51	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.4	19
52	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 2858-2864.	0.4	143
53	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.4	87
54	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- γ and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.4	88

#	ARTICLE	IF	CITATIONS
55	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	2.3	17
56	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004, 113, 709-717.	3.9	64
57	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <i>International Journal of Cancer</i> , 2003, 105, 384-389.	2.3	28
58	Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. <i>Vaccine</i> , 2003, 21, 1317-1326.	1.7	57
59	The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. <i>Cancer Research</i> , 2003, 63, 2158-63.	0.4	34
60	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. <i>Cancer Research</i> , 2003, 63, 2728-32.	0.4	53
61	HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 314-323.	1.2	29
62	Immunoprevention of colorectal cancer: a future possibility?. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 1001-1014.	1.0	6
63	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002, 101, 11-16.	2.3	96
64	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. <i>Gene</i> , 2001, 274, 139-149.	1.0	46
65	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	4.2	218
66	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	2.3	75
67	Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response. <i>International Journal of Cancer</i> , 2000, 87, 574-581.	2.3	56
68	The prospects for cancer gene therapy. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1025-1032.	1.1	7
69	Concomitant Amplification and Expression of PAX7-FKHR and MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14). <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 139-145.	1.0	20
70	Dral Is a P53-Responsive Gene Whose Four and a Half Lim Domain Protein Product Induces Apoptosis. <i>Journal of Cell Biology</i> , 2000, 151, 495-506.	2.3	93
71	The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit. <i>American Journal of Pathology</i> , 2000, 157, 2123-2131.	1.9	73
72	Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. <i>Bone</i> , 2000, 26, 215-220.	1.4	35

#	ARTICLE	IF	CITATIONS
73	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. , 2000, 87, 186.		3
74	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
75	Interferon (IFN)- β Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN- α . American Journal of Pathology, 1999, 154, 1211-1222.	1.9	38
76	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. Clinical and Experimental Metastasis, 1998, 16, 123-128.	1.7	10
77	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. British Journal of Cancer, 1998, 78, 1541-1546.	2.9	11
78	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
79	Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: Lack of autocrine growth modulation. , 1998, 78, 441-445.		10
80	The Immune Response Elicited by Mammary Adenocarcinoma Cells Transduced with Interferon- β and Cytosine Deaminase Genes Cures Lung Metastases by Parental Cells. Human Gene Therapy, 1998, 9, 217-224.	1.4	30
81	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. Journal of Experimental Medicine, 1998, 188, 589-596.	4.2	291
82	Is mts1 (S100A4) Gene Involved in the Metastatic Process Modulated by Gamma-Interferon?. Pathobiology, 1998, 66, 38-40.	1.9	3
83	INTERLEUKIN 6 GENE-TRANSFECTED MOUSE MAMMARY ADENOCARCINOMA: TUMOUR CELL GROWTH AND METASTATIC POTENTIAL. , 1997, 182, 76-85.		6
84	Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. , 1997, 71, 732-736.		17
85	Therapy of murine mammary carcinoma metastasis with interferon β and MHC gene-transduced tumour cells. British Journal of Cancer, 1996, 74, 1564-1569.	2.9	8
86	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by β -interferon transfectants through host lymphocytes. International Journal of Cancer, 1995, 61, 425-430.	2.3	12
87	Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. British Journal of Cancer, 1995, 72, 1224-1229.	2.9	42
88	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. International Journal of Cancer, 1994, 59, 269-274.	2.3	16
89	Inhibition of tumor growth and enhancement of metastasis after transfection of the β -interferon gene. International Journal of Cancer, 1993, 55, 320-329.	2.3	89
90	Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Research and Treatment, 1993, 28, 251-260.	1.1	42

#	ARTICLE	IF	CITATIONS
91	Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. <i>British Journal of Cancer</i> , 1993, 68, 862-867.	2.9	10
92	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1993, 67, 674-679.	2.9	18
93	Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination. <i>British Journal of Cancer</i> , 1992, 65, 519-522.	2.9	14
94	Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. <i>International Journal of Cancer</i> , 1991, 48, 270-276.	2.3	27
95	Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. <i>Clinical and Experimental Metastasis</i> , 1990, 8, 215-224.	1.7	39
96	Modulation by Ifn-Gamma of the Metastatic Ability of Murine, Human, and H-2-Transfected Tumor Cells. <i>Tumori</i> , 1989, 75, 383-388.	0.6	2
97	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1281-1286.	0.9	16
98	Interferon-Mediated Modulation of Metastasis and MHC Antigens. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 129-139.	0.8	3
99	Heterogeneity and Clonal Interactions in the TS/A Murine Mammary Adenocarcinoma. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 5-14.	0.8	4
100	Interferon-mediated enhancement of metastasis. Are MHC antigens involved?. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 277-287.	1.7	29
101	RMZ: A new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. <i>British Journal of Cancer</i> , 1986, 54, 1009-1014.	2.9	32
102	Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1986, 4, 13-23.	1.7	2
103	Colony-stimulating activity from the new metastatic TS/A cell line and its high- and low-metastatic clonal derivatives. <i>British Journal of Cancer</i> , 1985, 52, 215-222.	2.9	12
104	High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1984, 2, 251-259.	1.7	20
105	TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 1983, 1, 373-380.	1.7	203
106	Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. <i>Cancer</i> , 1982, 49, 623-632.	2.0	28
107	The occurrence of multiple steroid hormone receptors in disease-free and neoplastic human ovary. <i>Cancer</i> , 1981, 47, 1297-1302.	2.0	75
108	Multiple steroid hormone receptors in normal and abnormal human endometrium. <i>Journal of Cancer Research and Clinical Oncology</i> , 1980, 98, 173-183.	1.2	24

#	ARTICLE	IF	CITATIONS
109	Correlation between clinical response to antiandrogenic therapy and occurrence of receptors in human prostatic cancer. <i>Urology</i> , 1980, 16, 245-249.	0.5	14
110	17 β -estradiol, 5 α -Dihydrotestosterone, Progesterone and Cortisol Receptors in Normal and Neoplastic Human Endometrium. <i>Tumori</i> , 1979, 65, 241-253.	0.6	22
111	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. <i>Oncology Reports</i> , 0, , .	1.2	2